Business
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical
About this update from Chemocentryx Inc.
[{"type":"text","content":"-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston, MA. ChemoCentryx Poster Presentations at SITC 37th Annual Meeting (November 8-12, 2022): Results From an Ongoing Open-Label, Multicenter, Phase 1 Trial of CCX559, an Orally Administered Small Molecule PD-L1 Inhibitor, in Patients with Advanced Solid Tumors Abstract Number: 769Location: Hall CPresentation Time: November 10, 2022, 11:40 a.m. – 1:10 p.m. ETPoster Viewing Time: November 10, 2022, 9:00 a.m. – 9:00 p.m. ET The Small Molecule PD-L1 Inhibitor CCX559 Preferentially Accumulates in Tumors, Resulting in Depletion of Cell-Surface PD-L1 in a Murine Preclinical Model Abstract Number: 499Location: Hall CPresentation Time: November 10, 2022, 11:40 a.m. – 1:10 p.m. ETPoster Viewing Time: November 10, 2022, 9:00 a.m. – 9:00 p.m. ET About CCX559 CCX559 is a highly potent orally administered small molecule PD-L1 checkpoint inhibitor. Preclinical characterization has demonstrated that CCX559 blocks binding to PD-1 and CD80, and prevents PD-L1 inhibition of T cell activation. CCX559, when orally administered in animal models, demonstrated anti-tumor efficacy, including the ability to induce complete responses. The PD-L1/PD-1 interaction is one of the major immune checkpoints that limits the ability of effector T cells to destroy cancer cells. As a potential next generation therapy, an orally administered small molecule inhibitor of PD-L1 could have advantageous properties compared to approved monoclonal antibodies, such as better penetration into solid tumors, reduced immunogenicity, lack of Fc-mediated side effects and convenience of oral administration. During 2021, ChemoCentryx initiated a first-in-human Phase I dose escalation study to evaluate the safety, tolerability, PK, and PD of CCX559 in patients with various types of advanced cancer. In early 2023, the Company plans to advance CCX559 into a P...